Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Oct;6(10):589-98.
doi: 10.1038/nrrheum.2010.141. Epub 2010 Sep 7.

Using pharmacokinetic principles to optimize pain therapy

Kay Brune  1 , Bertold Renner, Burkhard Hinz
Affiliations
Review

Using pharmacokinetic principles to optimize pain therapy

Kay Brune et al. Nat Rev Rheumatol. 2010 Oct.

Abstract

Cyclo-oxygenase (COX) inhibitors are widely used to relieve musculoskeletal pain. These agents block the production of prostaglandins (PGs) at sites of inflammation by inhibiting the activity of two COX enzymes necessary for PG production and normal organ homeostasis. Inhibition of PG production at sites unrelated to pain is associated with adverse drug reactions (ADRs). The degree of analgesic efficacy, as well as the incidence and the localization of ADRs, are critically influenced by the pharmacokinetics (absorption, distribution and elimination) of these drugs. Ideally, sufficient and permanent inhibition of COX enzymes should be achieved in target tissues, with minimal ADRs. To minimize underdosing or overdosing, which result in therapeutic failure or ADRs, the COX inhibitor with the most appropriate pharmacokinetic properties should be selected on the basis of a thorough pharmacokinetic-pharmacodynamic analysis. In this Review, the pharmacokinetics of the prevailing COX inhibitors will be discussed and enigmatic aspects of these intensively used drugs will be considered.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Curr Med Res Opin. 1986;10(2):73-81 - PubMed
    1. J Mol Med (Berl). 2009 Oct;87(10):981-93 - PubMed
    1. Proc Natl Acad Sci U S A. 2002 May 14;99(10):7130-5 - PubMed
    1. Trends Pharmacol Sci. 2008 Aug;29(8):391-7 - PubMed
    1. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):28-33 - PubMed

MeSH terms